Abstract
Background The novel corona virus disease 2019 (COVID-19) pandemic has been causing a massive global public health havoc. Use of quinolones for treatment of COVID-19 was a matter of huge discussion in scientific community. Falsified data about efficacy of the drug against COVID-19 disseminated. This review was designed to study the dosages of chloroquine and hydroxychloroquine planned to be administered in clinical trials registered up to March 2020.
Summary Inclusion of chloroquine and hydroxychloroquine for COVID-19 treatment in Chinese national treatment guideline in the early days of the pandemic prompted numerous clinical trials in many countries to authenticate the efficacy of the drugs. Trials were designed to include chloroquine or hydroxychloroquine singly or in combination with other drugs. Almost all of the trials planned oral administration except few which used aerosol inhalation. In the later half of 2020, systematic reviews and results of those clinical trials point out the inefficacies and inadvertent adverse events due to the use of these quinolone drugs for COVID-19.
Conclusion This study reviews the various dosages of chloroquine and hydroxychloroquine utilized in published and under-study clinical trials as assessed during the end of March 2020. Specifically, clinical trials registered in Chinese and US trial registries were examined.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Not applicable
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We revised this article to reclarify our stand on the use of choloroquine and hydroxychloroquine for COVID-19. Multiple research and meta-analyses have shown that these drugs are ineffective to treat the disease. Data related to therapeutic dosages of chloroquine and chloroquine used for COVID-19 in registered clinical trials mentioned in this article are just for information and we do not promote their use in any sense.
Data Availability
No extra data required.